Legalon® 70 (Capsules) Instructions for Use
Marketing Authorization Holder
Meda Pharma, GmbH & Co. KG (Germany)
Manufactured By
Madaus GmbH (Germany)
ATC Code
A05BA03 (Silymarin)
Active Substance
Cardui mariae fructus (DAB German Pharmacopoeia)
Dosage Form
| Legalon® 70 | Capsules 70 mg: 20, 30, or 60 pcs. |
Dosage Form, Packaging, and Composition
Capsules are hard gelatin, size “2”, with a brown body and cap; the appearance of the capsule contents is a yellow powder.
| 1 capsule | |
| Dry extract of Silybum marianum fruit (36-44:1) | 86.5-93.35 mg, |
| Corresponding to a content of | |
| Silymarin | 70 mg, |
| Silymarin calculated as silybinin | 54.1 mg |
Excipients: polysorbate 80, povidone K25, mannitol, sodium carboxymethyl starch (type A), magnesium stearate.
Capsule shell composition: gelatin, iron oxide red dye (E172), titanium dioxide (E171), sodium lauryl sulfate, iron oxide black dye (E172).
10 pcs. – blisters (2) – cardboard packs.
10 pcs. – blisters (3) – cardboard packs.
10 pcs. – blisters (6) – cardboard packs.
Clinical-Pharmacological Group
Hepatoprotective agent
Pharmacotherapeutic Group
Hepatoprotective agent
Pharmacological Action
Herbal remedy. The main effect is hepatoprotective. Flavolignans, including silybin, dehydrosilybin, isosilybin, silymarin, dehydrosilymarin, silychristin, and taxifolin (2.8-3.8%), stabilize lysosomal and cell membranes, preventing the release of enzymes from cells.
They interact with free radicals and inhibit lipid peroxidation processes. Due to their antioxidant action, they hinder the penetration of various toxins (including chlorinated hydrocarbons, alpha-amanitin from the death cap mushroom, nitrosamines) into liver cells.
Silybin, silymarin, and their derivatives stimulate specific RNA polymerase A, resulting in the activation of protein and phospholipid synthesis in hepatocytes, and the acceleration of regeneration and detoxification processes in the liver.
The normalization of metabolic processes is facilitated by the tocopherols, macro- (potassium, magnesium) and microelements (copper, selenium) contained in the fruit.
The fatty oil of the fruit (20-34%) contains a large amount of unsaturated fatty acids (including linoleic acid – 50-62%), which have redox properties, promote cholesterol oxidation, and together with beta-sitosterol, prevent atherosclerosis.
Mucilage polysaccharides (5%) have an enveloping and gastroprotective effect. The nitrogen-containing compound betaine improves the process of digestion and bile formation in the liver. Silybum marianum fruit has a lactogenic effect.
Indications
Conditions after viral and toxic hepatitis, liver injuries, abdominal surgeries; chronic hepatitis, hepatocholecystitis, biliary dyskinesia, pancreatitis, liver cirrhosis; toxic liver damage (including that caused by the use of aminoglycosides, tetracycline, immunosuppressants, NSAIDs, anti-tuberculosis drugs, barbiturates, tranquilizers; organic solvents; mushroom poisoning, heavy metal salts, halogenated hydrocarbons; in alcohol intoxication); hyperlipidemia, prevention of atherosclerosis.
ICD codes
| ICD-10 code | Indication |
| B15 | Acute hepatitis A |
| B16 | Acute hepatitis B |
| B17.1 | Acute hepatitis C |
| B18.0 | Chronic viral hepatitis B with delta-agent |
| B18.1 | Chronic viral hepatitis B without delta-agent |
| B18.2 | Chronic viral hepatitis C |
| E78.5 | Hyperlipidemia, unspecified |
| I70 | Atherosclerosis |
| K70 | Alcoholic liver disease |
| K71 | Toxic liver disease |
| K73 | Chronic hepatitis, not elsewhere classified |
| K74 | Fibrosis and cirrhosis of liver |
| K81.0 | Acute cholecystitis |
| K81.1 | Chronic cholecystitis |
| K82.8 | Other specified diseases of gallbladder and cystic duct (including dyskinesia) |
| K85 | Acute pancreatitis |
| K86 | Other diseases of pancreas |
| ICD-11 code | Indication |
| 1E50.0 | Acute hepatitis A |
| 1E50.1 | Acute hepatitis B |
| 1E50.2 | Acute hepatitis C |
| 1E51.0Z | Chronic hepatitis B, unspecified |
| 1E51.1 | Chronic viral hepatitis C |
| 1E51.2 | Chronic hepatitis D |
| 4A85.00 | Drug hypersensitivity-induced liver disease |
| 5C80.Z | Hyperlipoproteinaemia, unspecified |
| BD40.Z | Atherosclerosis of peripheral arteries, unspecified |
| DB93 | Fibrosis or cirrhosis of liver |
| DB94.Z | Alcoholic liver disease, unspecified |
| DB95.Z | Drug-induced or toxic liver disease, unspecified |
| DB97.2 | Chronic hepatitis, not elsewhere classified |
| DC12.0Z | Acute cholecystitis, unspecified |
| DC12.1 | Chronic cholecystitis |
| DC1Z | Diseases of gallbladder and biliary tract, unspecified |
| DC30.Z | Cystic disease of pancreas, unspecified |
| DC31.Z | Acute pancreatitis, unspecified |
| DC32.Z | Chronic pancreatitis, unspecified |
| DC35.Z | Other specified diseases of pancreas, unspecified |
| DC3Z | Diseases of pancreas, unspecified |
| DD94 | Functional disorder of the gallbladder |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take orally with a sufficient amount of water.
For adults and adolescents over 12 years, the standard dose is one 70 mg capsule taken three times daily.
Administer the capsules at regular intervals, preferably during or immediately after meals to improve tolerability.
For the treatment of severe liver conditions, such as toxic liver damage or cirrhosis, the dosage may be increased based on medical supervision.
In cases of acute intoxication, including mushroom poisoning, initiate treatment as soon as possible under direct medical guidance.
The standard course of treatment typically lasts for a minimum of several weeks; continue therapy until liver parameters normalize.
For long-term management of chronic conditions, the duration of use is determined by the treating physician.
Do not exceed the recommended daily dose of 210 mg (three capsules) unless specifically instructed by a doctor.
If a dose is missed, take it as soon as remembered; if it is near the time for the next dose, skip the missed dose and resume the regular schedule.
Adverse Reactions
Rarely laxative effect.
Contraindications
Hypersensitivity to Silybum marianum.
Special Precautions
There is a report of antagonistic interaction of silymarin with yohimbine and phentolamine.
Storage Conditions
Store at 2°C (36°F) to 30°C (86°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Ingavirin capsules 90mg, 10pcs
Daivobet, ointment, 30g
Picamilon pills 50mg, 60pcs
Belosalic, ointment, 30g
No-spa pills 40mg, 64pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Nootropil pills 800mg, 30pcs
OKI, sachets 80mg 2g, 12pcs
Arbidol, capsules 100mg, 40pcs
Cerebrolysin, solution for injection 2ml ampoules 10pcs 